STAT3 and neoplasm: In contrast, blocking JAK/STAT3 signaling with AZD1480 treatment barely had effects on the CSC invasive activity regardless of whether PDX or patient primary tumor stromal cells were involved in the invasion assays (Figure 5A,C).